NO20041351L - En metode for reduksjon av mortalitet og morbiditet forbundet med kritisk sykdom - Google Patents

En metode for reduksjon av mortalitet og morbiditet forbundet med kritisk sykdom

Info

Publication number
NO20041351L
NO20041351L NO20041351A NO20041351A NO20041351L NO 20041351 L NO20041351 L NO 20041351L NO 20041351 A NO20041351 A NO 20041351A NO 20041351 A NO20041351 A NO 20041351A NO 20041351 L NO20041351 L NO 20041351L
Authority
NO
Norway
Prior art keywords
critical illness
morbidity associated
reducing mortality
mortality
morbidity
Prior art date
Application number
NO20041351A
Other languages
English (en)
Norwegian (no)
Other versions
NO20041351D0 (no
Inventor
Joseph Anthony Jakubowski
Suad Efendic
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20041351D0 publication Critical patent/NO20041351D0/no
Publication of NO20041351L publication Critical patent/NO20041351L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20041351A 2001-10-01 2004-03-31 En metode for reduksjon av mortalitet og morbiditet forbundet med kritisk sykdom NO20041351L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32633001P 2001-10-01 2001-10-01
PCT/US2002/028123 WO2003028626A2 (en) 2001-10-01 2002-09-19 Glucagon-like peptides (glp-1) and treatment of respiratory distress

Publications (2)

Publication Number Publication Date
NO20041351D0 NO20041351D0 (no) 2004-03-31
NO20041351L true NO20041351L (no) 2004-06-30

Family

ID=23271764

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041351A NO20041351L (no) 2001-10-01 2004-03-31 En metode for reduksjon av mortalitet og morbiditet forbundet med kritisk sykdom

Country Status (19)

Country Link
US (2) US20040235726A1 (pl)
EP (1) EP1443952A4 (pl)
JP (1) JP2005523877A (pl)
KR (1) KR20040040482A (pl)
CN (1) CN1561224A (pl)
BR (1) BR0212620A (pl)
CA (1) CA2462543A1 (pl)
CZ (1) CZ2004441A3 (pl)
EA (1) EA200400501A1 (pl)
EC (1) ECSP045044A (pl)
HR (1) HRP20040258A2 (pl)
HU (1) HUP0600437A2 (pl)
IL (1) IL160631A0 (pl)
MX (1) MXPA04002996A (pl)
NO (1) NO20041351L (pl)
PL (1) PL373846A1 (pl)
SK (1) SK1432004A3 (pl)
WO (1) WO2003028626A2 (pl)
ZA (1) ZA200402557B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532691A (ja) 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
WO2003066084A1 (en) * 2002-02-07 2003-08-14 Novo Nordisk A/S Use of glp-1 compound for treatment of critically ill patients
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
DE60335608D1 (de) * 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
JP2007536214A (ja) 2003-12-16 2007-12-13 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１類似体
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
CN101258163B (zh) 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
JP2009534423A (ja) 2006-04-20 2009-09-24 アムジェン インコーポレイテッド Ｇｌｐ−１化合物
JP2010043001A (ja) * 2006-11-09 2010-02-25 Sanwa Kagaku Kenkyusho Co Ltd Ｇｌｐ−１誘導体とその用途
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
ES2561208T3 (es) 2008-09-12 2016-02-25 Novo Nordisk A/S Método de acilación de un péptido o una proteína
US8889618B2 (en) 2008-11-07 2014-11-18 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (GLP-1)
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
DE102009024229B3 (de) * 2009-06-08 2010-10-14 Salzsieder, Eckhard, Dipl.-Phys., Dr. rer.nat. Indikationseinrichtung zur automatisierten Bestimmung des individuellen Inkretin-Sensitivitäts-Indexes eines Probanden
JP2013530993A (ja) 2010-07-02 2013-08-01 アンジオケム インコーポレーテッド 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
US9452225B2 (en) * 2012-03-01 2016-09-27 Novo Nordisk A/S GLP-1 prodrugs
WO2021222535A1 (en) * 2020-05-01 2021-11-04 Irazu Bio Method for treating respiratory viral infections comprising administration of fatty acid compositions
CN116847868A (zh) * 2021-01-29 2023-10-03 韩美药品株式会社 用于预防或治疗肺部疾病的包括gip衍生物或其长效共轭物的药学组合物
CN118344462B (zh) * 2024-06-18 2024-11-08 苏州易合医药有限公司 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
MY155270A (en) * 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6271241B1 (en) * 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors

Also Published As

Publication number Publication date
CN1561224A (zh) 2005-01-05
ECSP045044A (es) 2004-04-28
JP2005523877A (ja) 2005-08-11
NO20041351D0 (no) 2004-03-31
WO2003028626A2 (en) 2003-04-10
PL373846A1 (pl) 2005-09-19
SK1432004A3 (sk) 2005-03-04
MXPA04002996A (es) 2004-07-15
EP1443952A2 (en) 2004-08-11
HUP0600437A2 (en) 2006-09-28
EP1443952A4 (en) 2005-09-07
US20080032932A1 (en) 2008-02-07
CZ2004441A3 (cs) 2004-11-10
CA2462543A1 (en) 2003-04-10
EA200400501A1 (ru) 2005-06-30
US20040235726A1 (en) 2004-11-25
WO2003028626A3 (en) 2003-10-09
ZA200402557B (en) 2005-05-09
KR20040040482A (ko) 2004-05-12
HRP20040258A2 (en) 2004-12-31
BR0212620A (pt) 2005-09-20
IL160631A0 (en) 2004-07-25

Similar Documents

Publication Publication Date Title
NO20041351L (no) En metode for reduksjon av mortalitet og morbiditet forbundet med kritisk sykdom
TW200510528A (en) Polypeptide inducing apoptosis
IL193219A (en) Multi-detection of heartbeat to reduce error probability
EP1411968A4 (en) GLP 1 EXENDIN 4 PEPTIDE ANALOG AND THEIR USES
CY1108602T1 (el) Μεθοδος καθαρισμου της fsh
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
IT7919901A0 (it) Lega ternaria getterante non evaporabile e metodo di suo impiego per l'assorbimento di acqua,vapore d'acqua, di altri gas.
NO20034140L (no) Selvkjölende kondensert naturgass (LNG)
TWD101136S1 (zh) 錶殼
WO2005058252A3 (en) Glp-1 pharmaceutical compositions
WO2004074315A3 (en) Analogues of glp-1
DE60331891D1 (de) Kristalline komplexe von fluticasone 2-furoat
Raju et al. Estimation of stature from index and ring finger length in Davangere district
ZA98582B (en) Purification of electronic specialty gases by vapor phase transfilling
ID28119A (id) Pati yang dimodifikasi stabil-garam
TW200608990A (en) Cetp-vaccines
GB0218798D0 (en) Improvements to determination of ovulation
WO2001051511A3 (de) Rekombinante herstellung von humanen histon 1-subtypen sowie deren verwendung für therapeutische zwecke
SE9403593D0 (sv) Uppfinning för minskning av prestationsbehovet vid gång i trappor med normal steghöjd
SE0201366L (sv) Framställning av en frekvenskod ur en transformerad bild som representerar ett fingeravtryck att användas vid kontroll av en persons identitet
KR970006639Y1 (ko) 손목시계의 밴드
潘仕楷 " THE BEGINNING OF THE GOSPEL"-The Introductory Statement of Mark's Gospel (1: 1-3)
FR2816306B1 (fr) Procede de preparation de cetones fluorees
EP1319976A3 (en) Silver halide photographic materials containing solubilized antifoggants
TH64945S (th) รถหัดเดินโยกและเข็น